Open-label safety study of TMC114 in combination with low dose RTV and other ARVs in highly experienced HIV-1 infected patients with limited or no treatment options.

Registry ID

EUCTR2005-000793-45

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

Tibotec Pharmaceuticals Ltd.

Start date

2005-10-07

Completion date

2007-06-06

Last update

2026-08-16

Conditions

• HIV-1 infection
• HIV-1 infected patient

Summary

The primary objective is to provide early access to TMC114 for highly ARV-experienced HIV-1 infected patients who have failed and exhausted treatment options based on commercially available ARVs.

Locations

• , , Germany
• , , Italy

Related clinical trials

• Phase 3 Double-Blind Multicenter Randomized Active-Controlled Study to Evaluate the Safety and Efficacy of Bictegravir/Lenacapavir Versus Biktarvy® (Bictegravir/ Emtricitabine/Tenofovir Alafenamide) in Virologically Suppressed People with HIV-1

View on source registry